In women, apoB was inversely related to breast cancer risk (HR: 0.92; 95% CI: 0.86–0.99), whereas in both genders, apoA-I was negatively linked to lung cancer risk (HR: 0.88; 95% CI: 0.80–0.97). Here, APOB is linked to lung cancer.